- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02879864
Effect on Fatigue of Light (Lux) Therapy in Patients With Cancer (EFFLUX)
Fatigue is a symptom most commonly associated with the diagnosis of cancer. Fatigue often appears before the diagnosis of cancer, is increasing during treatment with chemotherapy and persists for years after treatment in more than 35% of patients. Fatigue is the earliest and most important symptom described by cancer patients. Its prevalence in cancer chemotherapy patients is between 70 and 100%. Fatigue is more common to cancer patients and to the general population or other types of patients. Typically described as a lack of energy associated with mental disorders, fatigue related to cancer can be extremely debilitating. The causes are many, mainly including the cancer itself, side effects due to treatment, sleeplessness due to pain, anxiety or depression. The cancer-related fatigue has a negative and significant direct impact on all aspects of the patient's quality of life, especially the physical, social and behavioral. Despite the availability of certain treatments and the advanced biomedical research, fatigue remains an inevitable consequence of cancer and its treatment.
The therapeutic use of natural light in medicine dates back to the late nineteenth century. Its remarkable effect on the stimulation of the immune system and fight against infections caused the development of the first therapy techniques (also called luxthérapie) awarded in 1903 by the Nobel Prize in medicine and physiology. Light plays a fundamental role in the regulation of circadian rhythms and homeostatic. The mechanism of action passes through a path "non-visual" involving melanopsin ganglion cells located in the retina. Activation of the pineal gland (epiphysis) by melanopsin cells allows transduce information "shadow and light" in melatonin synthesis from serotonin. Today, the effectiveness of the therapy is well established for treating fatigue-related disorders such as chronic fatigue, seasonal depression or seasonal or non-certain sleep disorders and in which the melatonin metabolism is disturbed. Light therapy, by its mechanism of action, allows reprogramming "of the biological clock and improved synchronization of circadian rhythms.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypotheses
Some studies have shown an inverse relationship between cancer-related fatigue and the time of exposure to natural light for cancer patients. This association suggests the existence of a vicious circle of side effects of chemotherapy (physical fatigue and moral), itself causing a decrease in outdoor activity and therefore a reduction of the light exposure time natural. This results in a strengthening of the initial patient's state of fatigue. In an interesting way, vitamin D synthesized in large part due to light plays a cancer protective role], especially in the prevention and treatment of pancreatic cancer for example. Furthermore and paradoxical way, the disruption of circadian rhythms is correlated to the development and tumor progression in vitro, in vivo tumor growth and incidence of cancer in humans.
Notoriously, the direct effect of light therapy on cancer-related fatigue has been little discussed in the literature. Data obtained from a small sample of patients indicate that light therapy improves quality of life by reducing fatigue in patients with breast cancer during chemotherapy. To date, There are no data on the effects of light therapy on cancer-related fatigue in general, patients treated with chemotherapy.
The purpose of this pilot study is to evaluate the role of light therapy on cancer-related fatigue in patients during the 6 months following initiation of first-line chemotherapy.
Primary objective
To assess the effects of daily therapy on fatigue of patients with locally advanced or metastatic cancer treated with chemotherapy.
secondary objective
Evaluate the impact of daily light therapy on quality of life, pain, anxiety and depression, tolerance of chemotherapy and medico-economic benefits.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Lionel STAUDACHER, MD
- Phone Number: +33 1 44 12 70 33
- Email: lstaudacher@hpsj.fr
Study Contact Backup
- Name: Helene BEAUSSIER, PhD, PharmD
- Phone Number: +33 1 44 12 70 38
- Email: hbeaussier@hpsj.fr
Study Locations
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75014
- Groupe hospitalier Paris saint Joseph
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Cancer histologically or cytologically confirmed (regardless of type)
- Patient eligible for first-line chemotherapy
- Life expectancy> 3 months
- WHO PS ≤ 2
- Age ≥ 18 years
- Informed consent signed and dated
- Affiliation to a social security scheme
Exclusion Criteria:
- Macular degeneration
- Diabetic retinopathy
- Glaucoma
- untreated cataract
- Patient treated with vitamin D
- Psychiatric disorders (bipolar disorder, paranoia, schizophrenia)
- For patients with other comorbidities may indicate against-the practice of therapy: application specialist opinion (ophthalmologist or psychiatrist)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Light therapy
Light therapy takes place in the patient's home the day following receipt of the equipment and for at least 7 days before the start of chemotherapy and according to current recommendations: daily exposure to a high intensity light (10,000 lux) in the morning at a time to be adapted to the patient according to his chronotype), for 30 minutes.
Light therapy begins immediately after receipt of the luminometer.
The total duration of daily outpatient therapy program is 6 months.
A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at the inclusion visit and at weeks 12 and 24.
They will complete the same day or the day before, and / or before any chemotherapy.
A follow-up visit will be performed 1 month after the end of therapy (week 28).
|
The light therapy, 6 month's program, is occurring at patient's home the day after device's reception and during at least 7 days before chemotherapy's beginning.
The ambulatory light program is daily exposure to a high-intensity light (10,000 lux) in the morning, at a time adapted to the patient according to his chronotype for 30 minutes.
The light source should be placed at eye level (distance of about 40 cm).
A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24, which will be completed the same day or the day before, and / or before any chemotherapy.
These questionnaires will be also completed during the follow-up visit 1 month after the last visit (week 28).
|
Active Comparator: usual care
usual care in oncology: The patient will be taken care of according to local chemotherapy in routine care and the recommendations.
A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24.
They will complete the same day or the day before, and / or chemotherapy before .
A follow-up visit will be performed 1 month after the last visit (week 28).
A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before
|
The patient will be taken care of according to local chemotherapy in routine care and the recommendations.
A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24.
They will complete the same day or the day before, and / or chemotherapy before.
A follow-up visit will be performed 1 month after the last visit (week 28).
A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of change of Tiredness: PIPER Score
Time Frame: Day 1, week 12, week 24 and week 28
|
Tiredness: PIPER Score (main variable) (22 items targeted in 4 dimensions: behavioral tiredness / intensity, emotional, sensory and cognitive / mood)
|
Day 1, week 12, week 24 and week 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of change of Quality of life (EORTC-QLQ-C30 SCORE)
Time Frame: Day 1, week 12, week 24 and week 28
|
Quality of life related to health: EORTC-QLQ-C30 (30 items targeted in 4 dimensions: the overall quality of life, fatigue, physical functioning and pain).
|
Day 1, week 12, week 24 and week 28
|
Assessment of change of Health General condition WHO SCORE
Time Frame: Day 1, week 12, week 24 and week 28
|
General condition: WHO
|
Day 1, week 12, week 24 and week 28
|
Assessment of change of Pain SCORE
Time Frame: Day 1, week 12, week 24 and week 28
|
Pain: BPI-Short Form (BPI-SF) and analgesic consumption
|
Day 1, week 12, week 24 and week 28
|
Assessment of change of Depression Scale
Time Frame: Day 1, week 12, week 24 and week 28
|
Depression / Anxiety: scale of depression and anxiety (HADS)
|
Day 1, week 12, week 24 and week 28
|
Assessment of change of slumber
Time Frame: Day 1, week 12, week 24 and week 28
|
Sleep: Pittsburgh questionnaire (PSQI)
|
Day 1, week 12, week 24 and week 28
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFFLUX
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
Clinical Trials on light therapy
-
University of HoustonCompleted
-
University of Colorado, BoulderRecruiting
-
University Hospital, Strasbourg, FranceCompleted
-
Uppsala UniversityUppsala County Council, SwedenCompletedDelayed Sleep Phase SyndromeSweden
-
Northwestern UniversityRecruitingAging | Peripheral Vascular Disease | Peripheral Artery Disease | Walking, DifficultyUnited States
-
Massachusetts General HospitalLiteCure LLCCompletedDepression | Major Depressive DisorderUnited States
-
Chinese University of Hong KongRecruiting
-
Medical University of ViennaCompletedSeasonal Affective DisorderAustria
-
Universidade Federal de Sao CarlosFundação de Amparo à Pesquisa do Estado de São Paulo; Centro de Pequisas de...Completed
-
Centre Psychothérapique de NancyLUCIMEDCompletedMajor Depressive Disorder | Unipolar DepressionFrance